TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05814588

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anodal TDCS
Description: RehaCom software is a computer assisted cognitive rehabilitation, it targets six programs of brain including attention, memory, and higher executive function, visuo-motor abilities, visual filed, vocational abilities, each module is divided into further subsections there is 36 total subsections, we will work on 6 subsections in every week.~The aTDCS device is a battery operated, with a pair of rubber conductive electrodes (size 7×5cm) enclosed with sponge saturated pockets (pads).

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Anodal TDCS
Description: RehaCom software is a computer assisted cognitive rehabilitation, it targets six programs of brain including attention, memory, and higher executive function, visuo-motor abilities, visual filed, vocational abilities, each module is divided into further subsections there is 36 total subsections, we will work on 6 subsections in every week.~The aTDCS device is a battery operated, with a pair of rubber conductive electrodes (size 7×5cm) enclosed with sponge saturated pockets (pads).

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Anodal TDCS
Description: rehacom cognitive therapy will be provided to this group participants
Study: NCT06779071

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NPNP-001
Description: Description: NPNP-001 2ml per injection, once a week for 3 injections. Placebo(saline) 2ml per injection, once a week for 2 injections.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conjuran
Description: Description: Conjuran 2ml per injection, once a week for 5 injections.
Study: NCT05820399

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Organic Guayusa Extract
Description: Supplementation: Participants will supplement daily with organic guayusa extract, which is a caffeinated Amazonian 'super-leaf' belonging to the holly species that contains a very unique blend of polyphenol antioxidants and caffeine (\~20% caffeine, 30% chlorogenic acids, 5% catechins) during 6 weeks of high intensity exercise training. Investigators and participants will be blinded to condition.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will supplement daily with placebo (maltodextrin). Investigators and participants will be blinded to condition.
Study: NCT05851573

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial intervention
Description: an SLP-administered 5-week treatment focused on psychological well-being
Study: NCT05701358

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physiology-guided NCL PCI
Description: For RFR, PCI will be performed as per local practice for all lesions with RFR ≤0.89. For FFR, PCI will be performed as per local practice for all NCLs with FFR ≤0.80.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Angiography-guided NCL PCI
Description: PCI will be performed as per local practice
Study: NCT06436105

Intervention type: OTHER
Intervention: FICB
Description: FICB is applied to the patients after spinal anesthesia.

Intervention type: OTHER
Intervention: 4 in 1 block
Description: 4 in 1 block is applied to the patients after spinal anesthesia.
Study: NCT05352841

Intervention type: DIAGNOSTIC_TEST
Intervention: Salivary sample analysis
Description: The status of caries will be recorded based on the WHO recommendation, 1997. The children will then be divided into two groups depending on whether they are diagnosed caries (group I) or without carious lesions (group II).After the examination, unstimulated saliva will be collected for analysis (subject to all conditions in proper sampling and without contamination) in a sterile disposable laboratory container with a wide opening and lid. Patients will be asked to tilt their head slightly and not swallow or move their tongue or lips during the collection period. Instructions will be given to accumulate saliva in the mouth for a maximum of 2 minutes and he or she will be asked to spit the accumulated saliva into the receiving court. About 1 ml of unstimulated saliva will be collected.

Intervention type: DIAGNOSTIC_TEST
Intervention: Salivary sample analysis
Description: The status of caries will be recorded based on the WHO recommendation, 1997. The children will then be divided into two groups depending on whether they are diagnosed caries (group I) or without carious lesions (group II).After the examination, unstimulated saliva will be collected for analysis (subject to all conditions in proper sampling and without contamination) in a sterile disposable laboratory container with a wide opening and lid. Patients will be asked to tilt their head slightly and not swallow or move their tongue or lips during the collection period. Instructions will be given to accumulate saliva in the mouth for a maximum of 2 minutes and he or she will be asked to spit the accumulated saliva into the receiving court. About 1 ml of unstimulated saliva will be collected.
Study: NCT06345469

Intervention type: OTHER
Intervention: Patient blood management (PBM)
Description: PBM means the medical enhancement of the participants own hematopoietic reserve to treat anemia and to reduce the ill effects of disease and bleeding on hematopoiesis and homeostasis.

Intervention type: OTHER
Intervention: Patient blood management (PBM)
Description: PBM means the medical enhancement of the participants own hematopoietic reserve to treat anemia and to reduce the ill effects of disease and bleeding on hematopoiesis and homeostasis.

Intervention type: BIOLOGICAL
Intervention: Allogeneic transfusion
Description: transfusion of donor red cells
Study: NCT06066502

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Precision ventilation
Description: The intervention arm prioritizes mitigation of ventilator-induced-lung-injury by individualizing support to patient-specific mechanics in an integrated approach to limit overdistension and atelectrauma. This is accomplished in this arm by titration of tidal volume to limitation of driving pressure at 12 centimeters of water (cmH2O) or less and using esophageal manometry to titrate PEEP to a transpulmonary pressure of 0 cmH2O with adjustments in respiratory rate to allow for permissive hypercapnia and FiO2 adjustments to assure adequate oxygenation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Guided usual care ventilation
Description: The comparison arm allows clinician discretion when titrating PEEP and tidal volume, while setting general targets for allowable PEEP/FiO2 combinations, target range for SpO2, and target range for tidal volume. This arm applies routine best-practice guidelines. This includes maintenance of tidal volumes of 6-8 cc/kg of ideal body weight, limiting plateau pressures to 30 cmH2O or less and application of PEEP-FiO2 combinations which include a wide range of typical usual care with esophageal manometry only for data collection and not clinical adjustment.
Study: NCT05109572

Intervention type: OTHER
Intervention: Hospitalized
Description: It was developed by Addington et al. (1994) to measure the presence of depression and the severity of depressive symptoms in patients with schizophrenia. The scale consists of 9 items to assess depression and is answered with a four-point Likert scale. The validity and reliability of the scale in schizophrenia patients in the Turkish population was determined by Oksay et al. by (2000). In the reliability study, the Cronbach's alpha coefficient was found to be 0.88. The cut-off point of the scale was stated as 11.

Intervention type: OTHER
Intervention: Hospitalized
Description: It was developed by Addington et al. (1994) to measure the presence of depression and the severity of depressive symptoms in patients with schizophrenia. The scale consists of 9 items to assess depression and is answered with a four-point Likert scale. The validity and reliability of the scale in schizophrenia patients in the Turkish population was determined by Oksay et al. by (2000). In the reliability study, the Cronbach's alpha coefficient was found to be 0.88. The cut-off point of the scale was stated as 11.

Intervention type: OTHER
Intervention: Non-hospitalized with emergency care
Description: It is adapted from the Buss-Durkee Hostility Inventory by Buss and Perry (1992), the scale consists of 29 items and five-point Likert types. The scale is physical and verbal aggression, hostility, and anger. Questions 9 and 16 on the scale are reverse scored. The score value on the scale varies in direct proportion to the aggression, that is, the higher the score, the higher the aggression. The Cronbach Alpha internal consistency coefficients of the original version of the scale is defined as; 0.89 for physical aggression, 0.85 for physical aggression, 0.72 for verbal aggression, 0.77 for hostility, 0.83 for anger subscale.
Study: NCT05682833

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Non surgical periodontal therapy
Description: Subgingival ultrasonic debridement + manual root planning

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non surgical periodontal therapy
Description: Subgingival ultrasonic debridement + manual root planning
Study: NCT04710875

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Na-lactate
Description: intravenous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride
Description: Intravenous
Study: NCT04770506

Intervention type: OTHER
Intervention: Data extraction from medical files
Description: Data extraction from medical files

Intervention type: OTHER
Intervention: Data extraction from medical files
Description: Data extraction from medical files
Study: NCT04526600

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fidget ball
Description: Access to a prototype 'smart' fidget ball with pressure sensors embedded, that produces touch traces and transmits real time data
Study: NCT05227118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8189
Description: MK-8189 administered orally once a day (QD) at a titration via tablet in 4 mg and 12 mg dose strengths

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: MK-8189 matching placebo administered orally QD
Study: NCT05109572

Intervention type: OTHER
Intervention: Non-hospitalized and non-emergency care
Description: Developed by Cull and Gill (1989), it evaluates the probability of suicide in adolescents and adults. The Turkish validity and reliability of the scale were performed by Atlı et al (2009). The scale consists of 36 items and is answered as a four-point Likert-type scale as never or rarely, sometimes, often and often or always.

Intervention type: OTHER
Intervention: Non-hospitalized and non-emergency care
Description: Developed by Cull and Gill (1989), it evaluates the probability of suicide in adolescents and adults. The Turkish validity and reliability of the scale were performed by Atlı et al (2009). The scale consists of 36 items and is answered as a four-point Likert-type scale as never or rarely, sometimes, often and often or always.
Study: NCT05391997

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Cervical and Shoulder Retraction exercises
Description: 11 patients will receive cervical traction and modified cervical and shoulder retraction exercises (10 to 12 repetitions). The total treatment session will be of 20-25 minutes with a total intervention period of 6 weeks with 3 sessions per week on alternative days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cervical Extension Traction exercises
Description: 11 patients will receive cervical traction force for 10 seconds and extend the cervical spine. The total treatment session will be of 20-25 minutes with a total intervention period of 6 weeks with 3 sessions per week on alternative days
Study: NCT04875442

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Memowave emitting sounds
Description: Memowave is worn during one night and emits sounds to increase slow brain waves

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Memowave not emitting sounds
Description: Memowave is worn during one night and doesn't emit sounds
Study: NCT06508294

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 8 week artificial intelligence based posture exercises
Description: 8 week artificial intelligence based posture exercises
Study: NCT06186297

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cranberry extract
Description: polyphenol PAC-1

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cranberry extract
Description: polyphenol PAC-1
Study: NCT05017090

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: M-TAPA block
Description: After tracheal intubation, a high-frequency linear probe will placed in the sagittal direction at the 10th costal margin, and transversus abdominis, internal oblique, and external oblique muscles will be identified. A block needle will inserted with in-plane technique and 25 ml 0.25 bupivacaine will be applied to the lower aspect of the chondrium. The same procedure will be repeated on the contralateral side.
Study: NCT04781296

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CT with a photon-counting detector
Description: Enrolled subjects will complete an exam using the photon-counting CT, with or without IV contract as indicated. Images will then be compared with the previously acquired CT conducted as standard of care.
Study: NCT05017090

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard perioperative and postoperative multimodal analgesia
Description: The pain intensity during rest and motion will be evaluated with the 0-10 Numeric Rating Scale (NRS). Patients will receive standard multimodal analgesia comprising paracetamol, tenoxicam, and tramadol.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard perioperative and postoperative multimodal analgesia
Description: The pain intensity during rest and motion will be evaluated with the 0-10 Numeric Rating Scale (NRS). Patients will receive standard multimodal analgesia comprising paracetamol, tenoxicam, and tramadol.
Study: NCT05689892

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision Coach Sessions
Description: Participants in the intervention group and their families will be referred to the DC to meet independently and discuss recommended treatment pathways.~Multiple sessions may be necessary until a final decision is reached. All SDM consults will be done virtually using a secure videoconferencing platform. The Ottawa Family Decision Guide will be used to facilitate the discussion. A DA will be provided to the study participants in the form of information cards containing information about different treatment options in pediatric IBD. This includes administration schedule, side effects, risk of cancer, among others. The DA has been developed and provided by the Cincinnati Children's Hospital Medical Center and adapted to the Canadian setting with electronic version by this research group with approval from the authors.
Study: NCT04785118

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyoscine N Butylbromide
Description: Patients will receive IV hyoscine butyl-bromide 20 mg in 2 ml, just before spinal anaesthesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Patients received IV ondansetron 4 mg in 2 ml, just before spinal anaesthesia.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Patients received 2 ml of IV normal saline as a placebo just before spinal anaesthesia.
Study: NCT05286125

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: erector spinae plane (ESP) block
Description: Using the in plane technique, the needle will be advanced between the transverse process and erector spinae muscle. The correct location will be confirmed using 1ml of Local Anesthetic (LA) to view hydrodissection(12). 19ml of LA will be injected between the muscle and transverse process.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: oblique subcostal transverse abdominis plane (TAP) block
Description: An echogenic needle will be inserted in-plane until the needle tip reaches the fascia between the rectus abdominis and the transverse abdominis muscles. Once the needle enters the TAP plane, a dynamic injection can be performed by advancing the needle under ultrasound guidance laterally in the pocket created by the initial injection of 5 - 10 mL of local anesthetic; as the needle is advanced, the remaining local anesthetic will be injected. This allows for a more lateral spread of the local anesthetic
Study: NCT06034691

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pcsk9 inhibitor
Description: The treatment group received postoperative use of 140 mg of Ribavirin, administered every two weeks, with 140 mg administered subcutaneously for a total of 48 weeks. There was no additional intervention with lipid-lowering drugs in the control group.
Study: NCT02397668

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CorMatrix Cor TRICUSPID ECM Valve
Description: CorMatrix Cor TRICUSPID ECM Valve to replace a diseased tricuspid valve, including tricuspid valve disease secondary to congenital heart disease.
Study: NCT06122922

Intervention type: DRUG
Group type: OTHER
Intervention: Hyperpolarized Xe129
Description: Hyperpolarized Xenon Gas
Study: NCT04725916

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Showering
Description: Patients will be instructed to shower after surgery with drains in place

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Restriction of Showering
Description: Patients will be restricted from showering post operatively if they have drains in place
Study: NCT05781412

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: Anodal and Sham cerebellar tDCS will be used in each participant in a counterbalanced order

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: Anodal and Sham cerebellar tDCS will be used in each participant in a counterbalanced order

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: Anodal and Sham cerebellar tDCS will be used in each participant in a counterbalanced order

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: Anodal and Sham cerebellar tDCS will be used in each participant in a counterbalanced order

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: Anodal and Sham cerebellar tDCS will be used in each participant in a counterbalanced order

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: Anodal and Sham cerebellar tDCS will be used in each participant in a counterbalanced order
Study: NCT06043830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: Acetazolamide 250 mg 2 capsules by mouth nightly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: Acetazolamide 250 mg 2 capsules by mouth nightly

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sugar capsule manufactured to match encapsulated Acetazolamide 2 capsules by mouth nightly

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sugar capsule manufactured to match encapsulated Acetazolamide 2 capsules by mouth nightly
Study: NCT06533319

Intervention type: DRUG
Group type: OTHER
Intervention: sofosbuvir/velpatasvir
Description: Patients who qualify for the study will be provided with sofosbuvir/velpatasvir for chronic hepatitis C treatment.
Study: NCT05936723

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory Muscle Training - VIH
Description: The VIH group will train every second day with gradual progression based on session length and breathing frequency. Participants will begin with 3 minutes of exercise with a frequency of 20 breaths·min-1 during the first session and add no more than 1 minute or 2 breaths·min-1 with each consecutive session.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory Muscle Training - ITPL
Description: The IPTL group will train 5 days a week, twice a day, with at least 6 hours break between sessions. The session will consist of 30 dynamic inspiratory maneuvers with progressive overload based on gradually increased resistance. The VIH group will train every second day with gradual progression based on session length and breathing frequency. Participants will begin with 3 minutes of exercise with a frequency of 20 breaths·min-1 during the first session and add no more than 1 minute or 2 breaths·min-1 with each consecutive session.
Study: NCT05724927

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Animal assisted activity
Description: The interviews consist of a total of six interviews, including an introduction, four studies, and a termination. Interviews will be held individually in each person's own room in the nursing home. Materials such as plastic aquarium, fish, fish food, fish food scales that will be given to the individuals during the interviews will be taken to the institution by the researchers before and will be given to the elderly individuals in the second interview.
Study: NCT05937867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10353 Capsules 30 mg, Oral, QN for 14 days
Description: HS-10353 Capsules 30 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10353 Capsules 50 mg, Oral, QN for 14 days
Description: HS-10353 Capsules 50 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10353 Capsules matching placebo, 30mg, Oral, QN for 14 days.
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10353 Capsules matching placebo, 50mg, Oral, QN for 14 days
Description: Placebo
Study: NCT04565275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug ICP-192
Description: 1. Dose Escalation Phase ICP-192 will be taken by patients with advanced solid tumor and will be treated follow the 3+3 dose escalation scheme~2. Dose Expansion Phase ICP-192 will be taken by patients with urothelial carcinoma or cholangiocarcinoma with FGFR gene alterations and will be treated at a single dose defined from the Dose Escalation Phase.
Study: NCT05719740

Intervention type: DIAGNOSTIC_TEST
Intervention: osteocrin
Description: laboratory routine test

Intervention type: DIAGNOSTIC_TEST
Intervention: osteocrin
Description: laboratory routine test
Study: NCT05884814

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Morning exercise
Description: Between 6-10am participants will attend the gym and perform 10 min of warm up exercise, 3 sets of 7 resistance exercises ( leg press, calf press, leg curl, chest press, lateral raise, seated row and plank)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Afternoon exercise
Description: Between 4-8pm participants will attend the gym and perform 10 min of warm up exercise, 3 sets of 7 resistance exercises ( leg press, calf press, leg curl, chest press, lateral raise, seated row and plank)

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Habitual physical activity levels
Description: Participants will be asked to maintain their normal activity levels